 |
| 에스디바이오센서 CI (사진=에스디바이오센서) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] SD Biosensor announced on the 15th that it recorded sales of 182.4 billion won and operating loss of 123.8 billion won in the first quarter. Sales fell 86.9% year-on-year, and operating profit turned into a deficit.
SD Biosensor plans to improve its performance by licensing additional products by the end of this year, following the product line that obtained additional official approval in the first quarter. In addition, "C10," a biochemical test platform that can quantitatively diagnose levels of liver function and electrolytes in the blood, is also expected to be launched by the end of this year.
"After the merger and acquisition of Meridian Bioscience in January this year, one-off costs such as PPA (by accounting for the difference in fair value and book value for a certain period of time) depreciation costs, inventory reserves to ease inventory risks and foreign exchange losses were reflected," said an official at SD Biosensor.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
